Prevalence, Species Distribution and Resistance of Candidemia in Pediatric and Adult Patients in a Northeast Italy University Hospital

• Published in: Journal of fungi (Basel) 2024-10, Vol.10 (10), p.707
• Main Authors: Meneghello, Silvia, Bernabè, Giulia, Di Pietra, Giuseppe, Di Sopra, Sarah, Del Vecchio, Claudia, Cattelan, Anna Maria, Castagliuolo, Ignazio, Brun, Paola
• Format: Article
• Language: English
• Subjects: Adults; Antifungal agents; Azoles; bloodstream infections; Candida; Candidemia; Candidiasis; Care and treatment; Caspofungin; Children; Clinical isolates; Computer industry; Drug resistance in microorganisms; Epidemiology; Geographical distribution; Health aspects; Infections; Intensive care; Intensive care units; Medical research; Medicine, Experimental; Micafungin; Morbidity; Mortality; Neutropenia; non-albicans Candida; Older people; Patients; Pediatrics; Population studies; resistance; Slovenia; Species; Surveillance; uncommon Candida; United States
• ISSN: 2309-608X; 2309-608X
• DOI: 10.3390/jof10100707

Candidemia and invasive candidiasis (IC) are causes of morbidity and mortality in healthcare settings, with notable differences between children and adults. Understanding the species distribution and antimicrobial susceptibility profiles of clinical isolates can guide empiric therapy in patients at risk of IC. This study investigated the incidence and antifungal susceptibility patterns of yeasts involved in IC in pediatric and adult patients from 2019 to 2023. The average incidence of IC was 0.715 per 1000 patients, increasing over the study period; infants had the highest incidence rates. Over half of the IC episodes occurred in intensive care units (ICUs). Non- (NAC) species represented the most frequently isolated species in adults and children (55.96% and 50.0%, respectively), with the prevalence of (26.45% and 14.7%, respectively), (14.97% and 8.82%, respectively) and (4.36% and 2.94%, respectively). was identified in 14.7% of pediatric IC cases. In NAC species, antifungal resistance has also increased over the five years of the study: 69.12% were resistant to azoles and 7.35% were resistant to micafungin. Resistance was higher in pediatric patients. Our study highlights differences in IC characteristics between pediatric and adult populations and emphasizes the importance of targeted antifungal stewardship in ICU patients with NAC invasive infections.